Navigation Links
Liraglutide provides significantly better glucose control than,insulin glargine in phase 3 study

er the past 2-3 months and a decrease is therefore a measure of treatment effect. The higher the blood glucose the more glucose binds to haemoglobin (glycation).

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 23,600 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.

Further information:
Media: Investors:
Outside North America: Outside North America:
Elin K Hansen Mads Veggerby Lausten
Tel (direct):
(+45) 4442 3450 Tel (direct):
(+45) 4443 7919
ekh@novonordisk.com mlau@novonordisk.com

Katrine Sperling Hans Rommer
Tel (mobile):
(+45) 3079 6718 Tel (direct):
(+45) 4442 4765
krsp@novonordisk.com hrmm@novonordisk.com

In North America: In North America:
Sean Clements Christian Qvist Frandsen
Tel (direct):
(+1) 609 514 8316 Tel (direct):
(+1) 609 919 7937
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
2. Positive results from placebo-controlled phase IIa study in patients suffering from house dust mite allergy
3. Placebo-controlled Phase IIa Study with the Immunotherapeutic CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in Hay Fever Patients
4. Independent publication supports the profile of CeNeS phase II compound, CNS 5161
5. Isotechnikas independent data monitoring committee conducts review of phase 2b kidney transplant trial
6. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
7. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
8. 2007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion
Post Your Comments:
(Date:5/16/2008)..., -- Results demonstrating that TYKERB and trastu... extension of progression-free survival (PFS), --...he inside and,outside of the HER2 receptor may cre...trating activity of TYKERB alone despite patients,...umab and chemotherapy, LONDON and PHILADELPHIA, M...
(Date:5/16/2008)...s Statistically Significant Reductions in Selected...bstract to be published in 2008 Proceedings of the...nical Oncology, SAN DIEGO, May 16 /PRNewswire-Fir...ANX ) announced today that, in a registrational bi...a statistically significant reduction,in general d...
(Date:5/15/2008)...nical data highlight safety profile of BSI-201 in ...s -, BRISBANE, Calif., May 15 /- BiP...cal company developing novel cancer therapies,tod...hibitor, BSI-201, will,be presented at the 2008 Am... in Chicago., Findings will be presented from the...
(Date:5/15/2008)...ay 15 /- Schering-Plough,Co... science and treatment of,chronic hepatitis C viru...several clinical studies with PEGINTRON(TM) (pegin...combination therapy, as well as boceprevir, the,co...r, will be presented at,the 39th annual Digestive ...
Breaking Medicine Technology:GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 2ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 3ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 4ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 5BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 7Michigan State Medical Society Foundation Makes A Difference by Assisting Those in Crisis Shelters 4742 1Michigan State Medical Society Foundation Makes A Difference by Assisting Those in Crisis Shelters 4742 2CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350 1539 1CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350 1539 2SIEMENS AlliedBarton Methodist Hospital and Family Planning Council Win Human Resources Department of the Year Awards 4738 1SIEMENS AlliedBarton Methodist Hospital and Family Planning Council Win Human Resources Department of the Year Awards 4738 2Blue Cross of California Reaches Out to Members Impacted by Southern California Fires 4734 1Blue Cross of California Reaches Out to Members Impacted by Southern California Fires 4734 2
(Date:5/16/2008)... Consumers could report side effects, but critics ...RIDAY, May 16 (HealthDay News) -- Direct-to-consum...ee phone number that would allow consumers to repo...sted Friday. , The experts serve on a panel tha...uch phone numbers are already mandated by the FDA ...
(Date:5/16/2008)... Contract Covers More than 500 Workers, WASHI... 500 paramedics,and emergency medical technicians ...hington area have ratified their first-ever contra... these workers are now covered by a,strong contrac...rement,future," said Teamsters General President J...
(Date:5/16/2008)... Study finds chronic disease sufferers gain benefi...AY, May 16 (HealthDay News) -- Taking activated vi...moderate to severe chronic kidney disease by about... two-year study of more than 1,400 patients, those...tivated vitamin D, had their overall risk of death...
(Date:5/16/2008)... PALM BEACH, Fla., May 16 /PRNewswire-USNewswi...ed more often by Americans, particularly our,child...9 individuals, have,significant hearing loss and t...n out of every 100 school age children have some f...tion to this social and economic problem,is what l...
Breaking Medicine News(10 mins):Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 3Health News:Vitamin D Use Linked to Lower Mortality in Kidney Patients 2Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 2Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 3
...arch has found that the cox-2 inhibitor celecoxib,...ay reduce the risk of the most common cause of br... shoring up blood vessels in a part of the brain t...icate and susceptible to dangerous bleeding, which...
...ased at the National Cancer Institute and Fred Hut...e, an antioxidant predominately found in tomatoes ...n fact, the researchers noted an association betwe...tioxidant related to lycopene, and an increased ri...
...to strengthen and sustain its leadership in the co...ive medicine, the University of Wisconsin-Madison...edicine Center. The announcement of the new cente...blic lecture by famed developmental biologist Ian ...
...ing towards making addition of folic acid to flour...of babies born with severe disabilities. After l...ncy (FSA) has said that it would approach the Gove...ns next month after it decides whether folic acid ...
Other Medicine News:Health News:Common Pain Killer may Reduce the Risk of Brain Damage in Premature Babies 2Health News:Common Pain Killer may Reduce the Risk of Brain Damage in Premature Babies 3Health News:Tomatoes are Not So Effective in Preventing Prostate Cancer 2Health News:UW Establishes Stem Cell and Regenerative Medicine Center 2Health News:UK too Will Insist on Folic Acid in Bread 2Health News:UK too Will Insist on Folic Acid in Bread 3
...ing more efficiency for high volume laboratories, ...provides extended walk away time. This high-speed ...up to 1600 photometric test results per hour (up t...ts on-board. Consolidate with Olympus 122 test men...
...Fit truly is a one size fits all plug. Once insert...inute period. As it hydrates, Form Fit increases i...licular cavity to form a perfect fit. ,The Form...nds into a soft, pliable, gelatinous material when...
Fully automated immunochemiluminometric assay for the rapid intraoperative,measurement of Intact PTH 1-84 using human serum or EDTA plasma.
...ariLite dual wavelength (532 nm and 940 nm) laser ... This solid-state laser quickly and effectively tr...vulgaris. VariLite offers the clinical versatility...s deeper, larger vessels in a convenient, affordab...
Medicine Products: